A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy.

Kohler, J A; Imeson, J; Ellershaw, C; Lie, S O

Kohler, J A; Imeson, J; Ellershaw, C; Lie, S O.

Affiliation

Kohler JA; Child Health, Southampton General Hospital, Southampton, United Kingdom.

Br J Cancer ; 83(9): 1124-7, 2000 Nov.

Article in En | MEDLINE | ID: mdl-11027423

ABSTRACT

ABSTRACT

One hundred and seventy-five children with Stage 3 or 4 neuroblastoma who had obtained a good response to conventional therapy were randomly allocated to 13-Cis retinoic acid at a dose of 0.75 mg/kg/day or placebo for up to 4 years. Toxicity was mild but no advantage in event-free survival was shown for the children receiving retinoic acid.

Subject(s)

Isotretinoin/therapeutic use; Neuroblastoma/drug therapy; Adolescent; Adult; Antineoplastic Agents, Alkylating/therapeutic use; Cheilitis/chemically induced; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Infant; Isotretinoin/adverse effects; Melphalan/therapeutic use; Neoplasm Staging; Neoplasm, Residual/drug therapy; Neoplasm, Residual/pathology; Neuroblastoma/mortality; Neuroblastoma/pathology; Skin Diseases/chemically induced; Survival Analysis; Survival Rate; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles / 7_ODS3_muertes_prevenibles_nacidos_ninos Database: MEDLINE Main subject: Isotretinoin / Neuroblastoma Type of study: Clinical_trials / Observational_studies / Prognostic_studies Limits: Adolescent / Adult / Child / Child, preschool / Humans / Infant Language: En Journal: Br J Cancer Year: 2000 Document type: Article

Fulltext

XML

PubMed Links

Search on Google